Scarica l'app Stockscreener
44.65
1.50%
-0.6195
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2025 Earnings Call Transcript - Insider Monkey
Mirum Pharmaceuticals (MIRM) Maintains Strong Buy Rating with Ra - GuruFocus
Mirum Pharmaceuticals (MIRM) Gets Price Target Boost to $77 | MI - GuruFocus
Trend Tracker for (MIRM) - news.stocktradersdaily.com
Mirum pharmaceuticals raises 2025 revenue guidance to $435M-$450M driven by robust growth - MSN
Mirum Pharmaceuticals (MIRM) Price Target Raised Following Stron - GuruFocus
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Beyond The Numbers: 4 Analysts Discuss Mirum Pharmaceuticals Stock - Benzinga
Mirum Pharmaceuticals (MIRM) Maintains Market Outperform Rating with Higher Price Target | MIRM Stock News - GuruFocus
Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised - MSN
Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL - Business Wire
Mirum Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
JMP raises Mirum Pharmaceuticals stock target to $76 By Investing.com - Investing.com Canada
Mirum Pharmaceuticals (MIRM) Price Target Raised Following Strong Revenue Outlook | MIRM Stock News - GuruFocus
Evercore ISI lifts Mirum stock target to $76, maintains outperform By Investing.com - Investing.com Canada
Evercore ISI lifts Mirum stock target to $76, maintains outperform - Investing.com
Mirum Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Earnings call transcript: Mirum Pharmaceuticals beats Q1 2025 revenue forecasts - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Mirum Pharmaceuticals beats Q1 estimates, raises 2025 guidance; shares rise - Investing.com Canada
Earnings Flash (MIRM) Mirum Pharmaceuticals Reports Q1 Revenue $111.6M, vs. FactSet Est of $98.4M - marketscreener.com
Earnings Flash (MIRM) Mirum Pharmaceuticals Reports Q1 Loss $0.30 Per Share, vs. FactSet Est of $-0.31 - marketscreener.com
Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - Stock Titan
Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities - Seeking Alpha
Learn to Evaluate (MIRM) using the Charts - news.stocktradersdaily.com
Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 - Business Wire
Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses - DutchNews.nl
Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? - Yahoo Finance
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Acquired by Russell Investments Group Ltd. - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $58.20 Consensus Target Price from Analysts - Defense World
Leerink Partnrs Issues Negative Outlook for MIRM Earnings - The AM Reporter
Research Analysts Offer Predictions for MIRM Q1 Earnings - Defense World
Geode Capital Management LLC Grows Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Are Analysts Optimistic? - simplywall.st
FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish - NewsBreak: Local News & Alerts
Mirum gets FDA nod for tablet version of liver drug, Livmarli - MSN
Mirum stock in focus after FDA nod for Livmarli tablet (MIRM) - Seeking Alpha
Mirum Pharmaceuticals Says FDA Approves Tablet Formulation of Treatment for Cholestatic Pruritus - marketscreener.com
Mirum'S Livmarli Now FDA Approved In Tablet Formulation - marketscreener.com
Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation - Business Wire
FDA Green Lights Game-Changing Tablet Version of Rare Liver Disease Drug LIVMARLI - Stock Titan
Mirum Pharma Expands Team with Major Equity Awards Package for Key New Talent - Stock Titan
Mirum Pharmaceuticals Inc [MIRM] stock was sold by Howe Jolanda at the price of US$0.11 million - knoxdaily.com
KLP Kapitalforvaltning AS Makes New $277,000 Investment in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Corebridge Financial Inc. - Defense World
Alagille Syndrome Market Growth to Accelerate in Forecast - openPR.com
(MIRM) Investment Report - news.stocktradersdaily.com
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Purchased by Teacher Retirement System of Texas - Defense World
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
MIRM Stock Sees Decline of Approximately -3.74% in Last Five Days - knoxdaily.com
Mirum Pharmaceuticals Says Livmarli Approved in Japan for Pruritus - MarketScreener
0.23%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):